01906nas a2200397   4500000000100000008004100001260001300042653001500055653001000070653000900080653001900089653003000108653001700138653001000155653000800165653002800173653003800201653001100239653001100250653001400261653001200275653003200287653000900319653001600328653001700344100001700361700001800378700001300396700001400409700001700423245006900440300000900509490000600518520097000524022001401494       1989                            d  c1989 Mar10aAdolescent10aAdult10aAged10aAutoantibodies10aBlood Coagulation Factors10aCardiolipins10aChild10aDNA10aEndocarditis, Bacterial10aEnzyme-Linked Immunosorbent Assay10aFemale10aHumans10aInfection10aleprosy10aLupus Coagulation Inhibitor10aMale10aMiddle Aged10aTuberculosis1 aSantiago M B1 aCOSSERMELLI W1 aTuma M F1 aPinto M N1 aOliveira R M00aAnticardiolipin antibodies in patients with infectious diseases.  a23-80 v83 a<p>IgG or IgM anticardiolipin antibodies were present in the sera of 67% of 33 patients with Hansen's disease, in 53% of 30 patients with tuberculosis and in 50% of 16 patients with endocarditis. Despite the high frequency of these antibodies, no patient had a history of thrombosis or abortion. Anti-denatured DNA antibodies were tested in patients with tuberculosis and patients with Hansen's disease. Only in the latter group did we observe a statistically significant association between anticardiolipin and anti-denatured DNA antibodies. Anticardiolipin binding activity, however, could not be inhibited by preincubation of sera with a variable concentration of denatured DNA. These data suggest that: a) Anticardiolipin antibodies in infectious diseases do not necessarily participate in the pathogenesis of thrombotic or obstetric complications; b) Anti-denatured DNA and anticardiolipin antibodies in the population studied do not have a cross-reaction.</p>  a0770-3198